An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens.

Trial Profile

An Open-label, Noncomparative, Multi-center, Emergency Use Protocol Administering Tigecycline for the Treatment of Subjects With Infections Due to Resistant Pathogens.

Completed
Phase of Trial: Phase III

Latest Information Update: 07 Feb 2013

At a glance

  • Drugs Tigecycline (Primary)
  • Indications Bacterial infections
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 07 Feb 2013 Actual end date Nov 2005 added as reported by ClinicalTrials.gov.
    • 07 Feb 2013 Actual initiation date changed from Sep 2003 to Jan 2004 as reported by ClinicalTrials.gov.
    • 09 Oct 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top